Adverum Biotechnologies Inc (ADVM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Adverum Biotechnologies Inc (ADVM) has a cash flow conversion efficiency ratio of 0.505x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.11 Million) by net assets ($-55.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Adverum Biotechnologies Inc (ADVM) net asset quality to measure how much of total assets are equity-financed.
Adverum Biotechnologies Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Adverum Biotechnologies Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ADVM cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Adverum Biotechnologies Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adverum Biotechnologies Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Caturkarda Depo Bangunan PT Tbk
JK:DEPO
|
0.013x |
|
GEA Grenobl. Elect.
PA:GEA
|
0.134x |
|
Loop Telecommunication International Inc
TW:3025
|
0.069x |
|
GSD Holding AS
IS:GSDHO
|
0.028x |
|
Cheil Electric Wiring Devices Co. Ltd.
KQ:199820
|
0.054x |
|
Ampire Co Ltd
TWO:8049
|
0.048x |
|
Roots Corp
TO:ROOT
|
0.300x |
|
Cosmax Nbt Inc
KQ:222040
|
0.204x |
Annual Cash Flow Conversion Efficiency for Adverum Biotechnologies Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Adverum Biotechnologies Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see ADVM company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $70.71 Million | $-92.46 Million | -1.308x | +3.31% |
| 2023-12-31 | $67.22 Million | $-90.90 Million | -1.352x | -127.09% |
| 2022-12-31 | $181.52 Million | $-108.09 Million | -0.595x | -74.61% |
| 2021-12-31 | $316.19 Million | $-107.83 Million | -0.341x | -86.82% |
| 2020-12-31 | $434.35 Million | $-79.29 Million | -0.183x | +35.04% |
| 2019-12-31 | $174.96 Million | $-49.17 Million | -0.281x | -4.77% |
| 2018-12-31 | $201.17 Million | $-53.96 Million | -0.268x | -8.69% |
| 2017-12-31 | $184.03 Million | $-45.42 Million | -0.247x | -38.70% |
| 2016-12-31 | $215.60 Million | $-38.37 Million | -0.178x | -27.20% |
| 2015-12-31 | $252.59 Million | $-35.34 Million | -0.140x | -270.27% |
| 2014-12-31 | $149.48 Million | $-5.65 Million | -0.038x | -100.38% |
| 2013-12-31 | $-218.00K | $-2.17 Million | 9.977x | +685.09% |
| 2012-12-31 | $-997.00K | $-1.27 Million | 1.271x | -- |
About Adverum Biotechnologies Inc
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is … Read more